Almost exactly two years ago, the venture firm Andreessen Horowitz took the wraps off a $200 million “biofund” that aimed to invest at the intersection of biology and engineering and was being led by its (then) new general partner, Vijay Pande. Pande argued at the time that it was finally possible to invest in software-enabled biotech ideas — without having to wait eons for… Read More
Permalink — http://feedproxy.google.com/~r/Techcrunch/~3/c_vcQAqCgmE/
URL of source article.
Date — December 14, 2017 11:00 am
Publish date of source article.
Source — http://feeds.feedburner.com/TechCrunch
URL of RSS feed.
Advertisements
